AMG 355 vs Azirkitig
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CCR8 · full Non-Small Cell Lung Cancer pipeline
AMG 355
Developed by Amgen
NCT06131398 · Phase 1 · completed
Everyone in the study knowingly received AMG 355, with no random assignment and no comparison group, so there is no way to separate the drug's effect from natural variation between patients. No results have been posted yet.
No aligned efficacy figure on record for this race.
Azirkitig
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AMG 355 | Azirkitig |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | —Not reported | —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- AMG 355
- —Not reported
- Azirkitig
- —Not reported
OS, median
- AMG 355
- —Not reported
- Azirkitig
- —Not reported
ORR
- AMG 355
- —Not reported
- Azirkitig
- —Not reported
Duration of response, median
- AMG 355
- —Not reported
- Azirkitig
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AMG 355: no structured comparison results are available for Non-Small Cell Lung Cancer.
Azirkitig: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AMG 355's landscape · Azirkitig's landscape